stented. In the SWEDEPAD 2 trial, the majority (91 %) is treated in the femoropopliteal segment and of these, 40 % are primarily stented. Conclusion-The SWEDEPAD trial is now halfway through the inclusion phase. No results are yet available. This trial explores the overall efficacy of drug-eluting technology in infrainguinal PAD interventions. The pragmatic clinical trial design, using a population-based registry with randomization functionality is a new and powerful tool for clinical vascular research.